| 產(chǎn)品名稱 | Nilotinib - AMN 107 | Tasigna |
| 產(chǎn)品貨號(hào) | Axon 1396 CAS [641571-10-0] MF C28H22F3N7OMW 529.52 Purity: 99% Soluble in DMSO Description A highly selective inhibitor of Bcr-Abl, the definitive cause of Ph+ CML, and its mutations References Certificates Categories Extra info H Kantarjian et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 2006, 354 (24), 2542–51. ? E Weisberg et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer 2006, 94,?1765-1769. ? JM Goldman, JV Melo. BCR-ABL in Chronic Myelogenous Leukemia - How Does It Work? Acta Haematol.?2008, 119, 212-217. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology BCR-ABL Oncogene Fusion Proteins EC 2.7.10.1 BCR-ABL inhibitor Chemical name 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino] benzamide Parent CAS No. [641571-10-0] Order Size Unit Price Stock 5 mg €70.00 In Stock |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Nilotinib - AMN 107 | TasignaAxon 1396 CAS [641571-10-0] MF C28H22F3N7O
Description
A highly selective inhibitor of Bcr-Abl, the definitive cause of Ph+ CML, and its mutations
BCR-ABL inhibitor
Chemical name4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino] benzamide Parent CAS No.[641571-10-0] |
| 產(chǎn)品資料 |
